Limits...
ALDH1 expression correlates with favorable prognosis in ovarian cancers.

Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J - Mod. Pathol. (2009)

Bottom Line: Expression of ALDH1 was found in 48.9% of the samples.Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02).High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ABSTRACT
Aldehyde dehydrogenase 1 (ALDH1), a detoxifying enzyme responsible for the oxidation of intracellular aldehydes, was shown to have a function in the early differentiation of stem cells, through its function in oxidizing retinol to retinoic acid. It has been shown that ALDH1 is a predictor of poor clinical outcome in breast cancer. The authors hypothesized that the level of ALDH1 expression may be correlated with the clinical outcome of patients with ovarian cancer. Immunohistochemical staining of ALDH1 expression was analyzed in 442 primary ovarian carcinomas using tissue microarray. The associations between the expression of the ALDH1 and clinical factors (diagnosis, tumor grade, stage, and clinical response to chemotherapy), as well as overall and disease-free survival, were analyzed. Expression of ALDH1 was found in 48.9% of the samples. Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02). High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test. In contrast to its function in breast cancer, ALDH1 was a favorable prognostic factor in ovarian carcinoma. ALDH1 therefore may have a different function in ovarian cancer than it does in breast cancer.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier survival curves for groups of ovarian carcinoma patients with low and high levels of ALDH1 expression. A, Overall survival curves in all patients with ovarian cancer (n = 440). B, Disease free survival curves in all patients (n = 440).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2692456&req=5

Figure 2: Kaplan-Meier survival curves for groups of ovarian carcinoma patients with low and high levels of ALDH1 expression. A, Overall survival curves in all patients with ovarian cancer (n = 440). B, Disease free survival curves in all patients (n = 440).

Mentions: Overall survival and disease free survival rates at 3 years, 5 years, and 10 years are shown in relation to the expression of ALDH1 in Table 3 and Table 4. At the time of this report, 88 of the 442 analyzed patients were alive without clinical evidence of ovarian carcinoma, 75 were alive with ovarian carcinoma, 262 had died of ovarian carcinoma, 15 were alive with unknown ovarian carcinoma status and 2 had been lost to follow-up which were excluded from the overall survival and disease-free survival analysis. A significant association between the expression of ALDH1 and overall survival (P <0.05) was observed. Patients who had tumors with >20% ALDH1-positive cells had better overall survival rate (P =0.01) and disease free survival rate (P =0.006) than patients who had tumors with <20% ALDH1-positive cells (Fig. 2).


ALDH1 expression correlates with favorable prognosis in ovarian cancers.

Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J - Mod. Pathol. (2009)

Kaplan-Meier survival curves for groups of ovarian carcinoma patients with low and high levels of ALDH1 expression. A, Overall survival curves in all patients with ovarian cancer (n = 440). B, Disease free survival curves in all patients (n = 440).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2692456&req=5

Figure 2: Kaplan-Meier survival curves for groups of ovarian carcinoma patients with low and high levels of ALDH1 expression. A, Overall survival curves in all patients with ovarian cancer (n = 440). B, Disease free survival curves in all patients (n = 440).
Mentions: Overall survival and disease free survival rates at 3 years, 5 years, and 10 years are shown in relation to the expression of ALDH1 in Table 3 and Table 4. At the time of this report, 88 of the 442 analyzed patients were alive without clinical evidence of ovarian carcinoma, 75 were alive with ovarian carcinoma, 262 had died of ovarian carcinoma, 15 were alive with unknown ovarian carcinoma status and 2 had been lost to follow-up which were excluded from the overall survival and disease-free survival analysis. A significant association between the expression of ALDH1 and overall survival (P <0.05) was observed. Patients who had tumors with >20% ALDH1-positive cells had better overall survival rate (P =0.01) and disease free survival rate (P =0.006) than patients who had tumors with <20% ALDH1-positive cells (Fig. 2).

Bottom Line: Expression of ALDH1 was found in 48.9% of the samples.Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02).High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ABSTRACT
Aldehyde dehydrogenase 1 (ALDH1), a detoxifying enzyme responsible for the oxidation of intracellular aldehydes, was shown to have a function in the early differentiation of stem cells, through its function in oxidizing retinol to retinoic acid. It has been shown that ALDH1 is a predictor of poor clinical outcome in breast cancer. The authors hypothesized that the level of ALDH1 expression may be correlated with the clinical outcome of patients with ovarian cancer. Immunohistochemical staining of ALDH1 expression was analyzed in 442 primary ovarian carcinomas using tissue microarray. The associations between the expression of the ALDH1 and clinical factors (diagnosis, tumor grade, stage, and clinical response to chemotherapy), as well as overall and disease-free survival, were analyzed. Expression of ALDH1 was found in 48.9% of the samples. Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02). High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test. In contrast to its function in breast cancer, ALDH1 was a favorable prognostic factor in ovarian carcinoma. ALDH1 therefore may have a different function in ovarian cancer than it does in breast cancer.

Show MeSH
Related in: MedlinePlus